Background: Levorphanol is a long-acting opioid analgesic that is an optical isomer of dextrorphan, a metabolite of the over-the-counter cough suppressant dextromethorphan. Providers prescribing levorphanol for pain management may need to assess compliance through urine drug testing, as this agent is subject to abuse. Therefore, it is important to differentiate between dextromethorphan and levorphanol ingestion.
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Pain Physician:March/April 2018; 21:E167-E171 E168 www.painphysicianjournal.com a clinical trial examined its use for neuropathic pain, and a study based on retrospective chart reviews evaluated patient response to the drug in both chronic nonmalignant and cancer pain (5, 8) . Multiple review articles have since advocated for providers to consider its clinical utility as an alternative to other opioids (1, 6, (9) (10) (11) (12) (13) (14) . As a result, there is an increased demand for levorphanol toxicology testing to assess treatment compliance (1) . The practice of urine drug testing for the purpose of opioid prescription compliance assessment is recommended in multiple pain management treatment guidelines (15) (16) (17) (18) . Medication compliance testing provides an objective tool for clinicians to assess the presence of prescribed medications and ensure the absence of illicit and nonprescribed medications (19, 20) . Because a portion of the metabolic pathway of dextromethorphan is shared with that of levorphanol, it may be difficult for providers to distinguish between dextromethorphan and levorphanol ingestion when assessing levorphanol compliance. This is concerning given that levorphanol is a schedule II controlled substance with abuse potential (7) . Following levorphanol consumption, dextromethorphan-specific markers should not be present; thus, the presence of dextromethorphan or 3-methoxymorphinan should strictly indicate dextromethorphan consumption. However, this has not been L evorphanol is a long-acting opioid analgesic that binds mu, delta, and kappa opioid receptors; additionally, it appears to decrease activity at N-methyl-D-aspartate (NMDA) receptors and block uptake of serotonin and norepinephrine (1) . It is an optical isomer (enantiomer) of dextrorphan, which is a metabolite of the over-the-counter (OTC) cough suppressant dextromethorphan. Enantiomers have the same molecular formula with a different structural arrangement of atoms, bearing a nonsuperimposable mirror image relationship. Conventional analytical techniques do not permit separation or differentiation of enantiomers. Dextromethorphan metabolizes to dextrorphan, 3-methoxymorphinan, and (+)-3-hydroxymorphinan. Levorphanol metabolizes primarily to levorphanol-3-glucuronide and norlevorphanol, or (-)-3-hydroxymorphinan (2-4). The metabolism of dextromethorphan and levorphanol is detailed in Fig. 1 .
Levorphanol was developed in 1949 as an alternative to morphine for chronic pain (5, 6) . Its use declined after the introduction of extended-release preparations of morphine, fentanyl, and oxycodone (5). It is now only commercially available in the United States as a 2 mg oral tablet (5, 7) . In more recent years, providers have expressed a renewed interest in utilizing levorphanol after 
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Identifying Levorphanol Using Urine Markers demonstrated in the literature to date, and anticipated urine concentrations of levorphanol/dextrorphan and 3-hydroxymorphinan following human levorphanol consumption has not been published. It is therefore unknown if urine concentrations of levorphanol/dextrorphan and 3-hydroxymorphinan lend interpretive guidance regarding which medication has been consumed.
The objectives of this retrospective data review were to investigate urine concentrations of levorphanol/dextrorphan and 3-hydroxymorphinan in healthcare patients, to characterize cases of potential levorphanol ingestion based on detection of relevant urine biomarkers, and to assess the need for an enantiomeric analysis to distinguish between dextromethorphan and levorphanol ingestion.
Methods
Medication compliance test results for 521 urine samples submitted to Aegis between July 2014 and July 2016 were evaluated for the presence of dextromethorphan, 3-methoxymorphinan, levorphanol/dextrorphan, and 3-hydroxymorphinan by liquid chromatographytandem mass spectrometry (LC-MS/MS) above the limit of quantitation (LOQ) of 10 ng/mL. All samples for which either dextromethorphan or levorphanol testing was requested on the laboratory requisition form were included in this data review. When provided, prescription information was obtained from the ordering physician as indicated on the laboratory requisition form. An enantiomeric analysis was not performed during laboratory testing; therefore, levorphanol was not differentiated from dextrorphan, and (-)-3-hydroxymorphinan (norlevorphanol) was not differentiated from (+)-3-hydroxymorphinan. Urine specimens underwent hydrolysis with β-glucuronidase.
Results
Urine concentrations and parent to metabolite ratios for levorphanol/dextrorphan and 3-hydroxymorphinan are provided in Table 1 . Of the 521 urine test results evaluated, 463 were from different sample donors (median age 49 years) in 112 physician practices across 33 states.
All samples with levorphanol listed as a prescribed medication had both levorphanol/dextrorphan and 3-hydroxymorphinan present. Dextromethorphan and 3-methoxymorphinan were also identified in one of these samples, indicating ingestion of dextromethorphan. Twenty-two samples with dextromethorphan listed as a prescribed medication did not have any detectable dextromethorphan or 3-methoxymorphinan present above the LOQ. Median concentrations of levorphanol/dextrorphan and 3-hydroxymorphinan for these samples were 125 ng/mL and 135 ng/mL, respectively. Of the samples without prescribed levorphanol or dextromethorphan indicated, 95 did not have dextromethorphan or 3-methoxymorphinan present above the LOQ. The median concentrations of levorphanol/dextrorphan and 3-hydroxmorphinan for these samples were 128 ng/mL and 86 ng/mL, respectively. discussion Urinary excretion of levorphanol in animals and levorphanol plasma concentrations in humans have been described elsewhere (3,4,21). To our knowledge, this is the first report identifying concentrations of levorphanol/dextrorphan and 3-hydroxymorphinan in human urine.
Metabolite concentrations are typically expected to exceed parent drug concentrations in urine, often resulting in a parent to metabolite ratio of less than one. A study in rats demonstrated that 45% of a levorphanol dose is excreted into the urine as glucuronide metabolites, while only 7% of the drug is excreted unchanged (3). If this excretion pattern holds true in humans, this data further supports an anticipated levorphanol to 3-hydroxymorphinan ratio of less than one. However, the median parent to metabolite ra- tio for all samples evaluated in this data review was greater than one. This observation may be attributed to the hydrolysis of glucuronide metabolites in the laboratory testing method, which converts levorphanol glucuronide back to free levorphanol. It has also been proposed that some hydrolysis of conjugated levorphanol occurs in vivo (1, 4, 22) . Of the 83 samples with dextromethorphan listed as a prescribed medication, 22 (26.5%) did not have any detectable dextromethorphan or 3-methoxymorphinan, suggesting the potential exists for patients prescribed levorphanol to ingest dextromethorphan and appear compliant with levorphanol therapy on a urine drug test. No prescription was indicated for either dextromethorphan or levorphanol for 419 samples. Neither dextromethorphan nor 3-methoxymorphinan was present above the LOQ for 95 (22.7%) of these samples; however, these patients were more likely to have ingested dextromethorphan since it is available without a prescription. These observations further suggest the potential for feigned levorphanol compliance on a urine drug test following dextromethorphan use. Though, illicit use of levorphanol cannot be ruled out for these samples, as it is a schedule II controlled substance with abuse potential (7). Dextromethorphan and 3-methoxymorphinan were detected in one sample with levorphanol listed as a prescribed medication. Detection of these dextormethorphanspecific markers indicates the patient either ingested dextromethorphan alone or in combination with levorphanol.
Since an enantiomeric analysis was not utilized with the LC-MS/MS testing method, levorphanol could not be differentiated from dextrorphan, and neither could (-)-3-hydroxymorphinan from (+)-3-hydroxymorphinan. The information presented in this study was derived from a retrospective data review, and hepatic and renal function of patients was not assessed. However, hepatic and renal function could impact the metabolism, excretion, and distribution of levorphanol biomarkers in urine. Furthermore, the dosage amount of levorphanol and/or dextromethorphan and time from last ingestion was not provided. Given these limitations, further investigation of levorphanol in human urine is warranted.
In conclusion, it may be impossible to distinguish between levorphanol and dextromethorphan ingestion based on urine biomarkers, unless dextromethorphan or 3-methoxymorphinan is present or an enantiomeric analysis is performed. Providers should consider the parameters of their laboratory's testing method when interpreting levorphanol urine drug test results.
